Skip to main content
Year archive

Inventiva — 2025 filings

All 105 regulatory filings released by Inventiva (IVA) in 2025, sourced directly from the official regulator.

105 Filings
2025 Period
2025 filings (105)
Filing Released Lang
Franchissements de seuils
Major Shareholding Notification
2025-12-15 French
Franchissement de seuils
Major Shareholding Notification
2025-12-15 French
Franchissement de seuils
Major Shareholding Notification
2025-12-15 French
Franchissement de seuil
Major Shareholding Notification
2025-12-05 French
Franchissement de seuil
Major Shareholding Notification
2025-12-02 French
Franchissement de seuils
Regulatory Filings
2025-12-01 French
Franchissement de seuils
Major Shareholding Notification
2025-11-28 French
Franchissement de seuils
Major Shareholding Notification
2025-11-28 French
Franchissement de seuils
Major Shareholding Notification
2025-11-28 French
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025
Declaration of Voting Results & Voting Rights Announcements
2025-11-28 French
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-11-28 English
Inventiva publie ses informations financières du 3ème trimestre 2025¹
Earnings Release 9M 2025
2025-11-21 French
Inventiva reports 2025 Third Quarter Financial Information¹
Earnings Release 9M 2025
2025-11-21 English
Franchissement de seuil
Major Shareholding Notification
2025-11-21 French
Franchissement de seuils
Major Shareholding Notification
2025-11-21 French
Franchissement de seuil
Major Shareholding Notification
2025-11-21 French
Franchissement de seuils
Major Shareholding Notification
2025-11-21 French
Inventiva annonce l’exercice intégral de l’Option des Banques portant le montant de l'Offre à environ 172,5 millions de dollars
Capital/Financing Update
2025-11-17 French
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Capital/Financing Update
2025-11-17 English
Inventiva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Capital/Financing Update
2025-11-13 French
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
Capital/Financing Update
2025-11-13 English
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au public d'American Depositary Shares d'approximativement 150 millions de dollars
Capital/Financing Update
2025-11-13 French
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Capital/Financing Update
2025-11-13 English
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Regulatory Filings
2025-11-13 French
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Capital/Financing Update
2025-11-13 English
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-11-06 English
Assemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
Report Publication Announcement
2025-11-06 French
Information relative au nombre total de droits de vote et d’actions composant le capital social au 20 octobre 2025
Share Issue/Capital Change
2025-11-06 French
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Report Publication Announcement
2025-11-06 English
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Capital/Financing Update
2025-10-14 French
Inventiva Announces the Implementation of a New ATM Program
Capital/Financing Update
2025-10-14 English
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025
Regulatory Filings
2025-10-07 French
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Regulatory Filings
2025-10-07 English
Inventiva annonce la nomination d’Andrew Obenshain au poste de Directeur Général
Board/Management Information
2025-10-01 French
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Board/Management Information
2025-10-01 English
Inventiva publie ses résultats financiers non audités du premier semestre 2025 et fait le point sur ses activités
Interim / Quarterly Report H1 2025
2025-09-29 French
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
Interim / Quarterly Report H1 2025
2025-09-29 English
RFS
Interim / Quarterly Report H1 2025
2025-09-29 French
Inventiva to Host Analyst and Investor Event on October 8, 2025
Report Publication Announcement
2025-09-24 English
Inventiva organise un événement analystes et investisseurs le 8 octobre 2025
Regulatory Filings
2025-09-24 French
Franchissement de seuils
Major Shareholding Notification
2025-09-08 French
Inventiva to Participate in Upcoming September Investor Conferences
Report Publication Announcement
2025-09-04 English
Franchissement de seuil
Major Shareholding Notification
2025-08-25 French
Franchissement de seuil
Major Shareholding Notification
2025-08-25 French
Franchissement de seuil
Major Shareholding Notification
2025-08-19 French
Franchissement de seuil
Major Shareholding Notification
2025-08-19 French
Franchissement de seuil
Major Shareholding Notification
2025-08-19 French
Franchissement de seuil
Major Shareholding Notification
2025-08-12 French
Franchissements de seuil
Major Shareholding Notification
2025-08-12 French
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Regulatory Filings
2025-08-11 English
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
Regulatory Filings
2025-08-11 French
Franchissement de seuil
Major Shareholding Notification
2025-08-11 French
Franchissement de seuil
Major Shareholding Notification
2025-08-11 French
Franchissement de seuils
Major Shareholding Notification
2025-08-11 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Transaction in Own Shares H1 2025
2025-07-31 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Transaction in Own Shares
2025-07-31 French
Inventiva publie ses informations financières préliminaires du premier semestre 2025¹
Earnings Release H1 2025
2025-07-29 French
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Earnings Release H1 2025
2025-07-29 English
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Board/Management Information
2025-07-09 English
Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementai
Board/Management Information
2025-07-09 French
Inventiva receives $10 million milestone payment from CTTQ
Regulatory Filings
2025-07-07 French
Inventiva receives $10 million milestone payment from CTTQ
Regulatory Filings
2025-07-07 English
Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des mod
Regulatory Filings
2025-07-02 French
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of
Regulatory Filings
2025-07-02 English
Franchissement de seuils
Major Shareholding Notification
2025-06-17 French
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Board/Management Information
2025-06-10 English
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la « UBS Spring Biotech Conference »
Regulatory Filings
2025-05-27 French
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Regulatory Filings
2025-05-27 English
Inventiva reports 2025 First Quarter Financial Information¹
Earnings Release Q1 2025
2025-05-23 English
Inventiva publie ses informations financières¹ du 1er trimestre 2025
Earnings Release Q1 2025
2025-05-23 French
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-05-23 English
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025
AGM Information
2025-05-23 French
Descriptif du Programme de Rachat d’Actions Pouvant Être Mis en Œuvre dans le Cadre du Contrat de Liquidité Conclu avec Kepler Chevreux
Transaction in Own Shares
2025-05-22 French
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Transaction in Own Shares
2025-05-22 English
Franchissement de seuil
Major Shareholding Notification
2025-05-16 French
Franchissements de seuils
Major Shareholding Notification
2025-05-15 French
Franchissement de seuil et déclaration d'intention
Major Shareholding Notification
2025-05-15 French
Franchissement de seuils
Major Shareholding Notification
2025-05-13 French
Franchissement de seuil
Major Shareholding Notification
2025-05-13 French
Inventiva obtient la deuxième tranche de 116 millions d'euros de son financement structuré d'un montant maximum de 348 millions d'euros
Capital/Financing Update
2025-05-05 French
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Capital/Financing Update
2025-05-05 English
Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires
AGM Information
2025-04-30 French
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
AGM Information
2025-04-30 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025
Declaration of Voting Results & Voting Rights Announcements
2025-04-30 French
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-04-30 English
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de
Regulatory Filings
2025-04-24 French
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanif
Report Publication Announcement
2025-04-24 English
DEU 2024
Annual Report (ESEF) FY 2024
2025-04-17 French
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F »)
Report Publication Announcement
2025-04-15 French
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Report Publication Announcement FY 2024
2025-04-15 English
Inventiva reports its 2024 full year results and provides a business update
Earnings Release FY 2024
2025-03-26 English
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
Earnings Release FY 2024
2025-03-26 French
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024
Report Publication Announcement
2025-03-19 French
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Report Publication Announcement
2025-03-19 English
Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor
Regulatory Filings
2025-02-26 French
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Regulatory Filings
2025-02-26 English
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1
Regulatory Filings
2025-02-20 French
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Regulatory Filings
2025-02-20 English
Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité
Earnings Release FY 2024
2025-02-10 French
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Earnings Release FY 2024
2025-02-10 English
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Capital/Financing Update
2025-01-24 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Regulatory Filings
2025-01-24 French
Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025
Earnings Release Q1 2025
2025-01-22 French
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Regulatory Filings
2025-01-22 English
Franchissement de seuil
Major Shareholding Notification
2025-01-16 French